Exhibit 10.2

 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS
DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN
ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION.

 

AMENDING AGREEMENT

 

This Amending Agreement (this “Amending Agreement”) is entered into and
effective this 13th day of March, 2014 (the “Effective Date”), by and between
Therapure Biopharma Inc. (“Therapure”), a Canadian corporation with its
principal place of business in Mississauga, Ontario and Insmed Incorporated
(“Insmed”), a Virginia corporation, having its principal office at 9 Deer Park
Drive, Suite C, Monmouth Junction, New Jersey. Each of Therapure and Insmed is
referred to herein as a “party” and collectively as the “parties”.

 

RECITALS

 

WHEREAS, Therapure and Insmed entered into a Commercial Manufacturing Agreement
effective the 7th day of February, 2014 (the “CMA”), for the manufacture of
ARIKACE™ (liposomal amikacin for inhalation);

 

AND WHEREAS, the parties desire to amend certain terms of the CMA in the manner
and on the terms and conditions set forth below;

 

AND WHEREAS, pursuant to Section 32.1 of the CMA, the CMA may not be amended,
except upon the execution and delivery of a written agreement by the parties.

 

NOW, THEREFORE, in consideration of the mutual covenants and agreements
contained herein, the parties agree as follows:

 

ARTICLE 1
CAPITALIZED TERMS

 

1.1.         Capitalized Terms. Unless otherwise defined in this Amending
Agreement, all capitalized terms used herein shall have the meaning given to
such terms in the CMA.

 

ARTICLE 2
AMENDMENTS TO CMA

 

2.1.         Amendments to CMA. The CMA is hereby amended as follows:

 

(i)                                     the first page of Schedule E (being, for
the avoidance of doubt, the Confidential — Capital Estimate (January 27, 2014))
is hereby deleted in its entirety and replaced with the document attached hereto
at Appendix I.

 

ARTICLE 3
REMAINING TERMS UNCHANGED

 

Remaining Terms Unchanged. Except as expressly amended as set forth herein, all
of the terms and conditions and provisions of the CMA are hereby confirmed to
continue in full force and effect, unamended, it being the intent that the CMA
shall henceforth be read and construed in conjunction with this Amending
Agreement. On and after the Effective Date, each reference in the CMA to the
“Agreement” shall be to the CMA as amended hereby. In the event

 

--------------------------------------------------------------------------------

 

that any provision of the CMA is deemed to be in conflict with the provisions of
this Amending Agreement, the provisions of this Amending Agreement shall
prevail.

 

ARTICLE 4
APPLICABLE LAW

 

4.1.         Applicable Law. This Amending Agreement shall be deemed to be made
in and in all respects shall be construed and interpreted and the rights granted
herein governed in accordance with the laws of the State of New York, regardless
of any laws or principles of conflicts of laws or rules that would cause the
application of the laws of any jurisdiction other than the State of New York.

 

ARTICLE 5
COUNTERPARTS

 

5.1.         Counterparts. This Amending Agreement may be executed in
counterparts, each of which shall constitute an original and all of which
together shall constitute one and the same instrument. This Amending Agreement
may be executed by fax or other electronic transmission with the same binding
effect as original ink signatures.

 

ARTICLE 6
AUTHORITY

 

6.1.         Authority. The parties executing this Amending Agreement on behalf
of Insmed and Therapure represent and warrant that they have the authority to
enter into this Agreement and to bind their respective companies to all the
terms and conditions of this Amending Agreement.

 

ARTICLE 7
GENERAL

 

7.1.         General. Articles 18, 24, 27, 28, 32 and 38 of the CMA shall apply
to this Amending Agreement mutatis mutandis.

 

[THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK;
SIGNATURE PAGE TO FOLLOW]

 

--------------------------------------------------------------------------------

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS
DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN
ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION.

 

2

--------------------------------------------------------------------------------

 

IN WITNESS WHEREOF, the undersigned have caused this Amending Agreement to be
signed by their duly authorized representatives as of the date first written
above.

 

 

THERAPURE BIOPHARMA INC.

 

 

 

 

By:

 

/s/ Nicholas Green

 

 

Name:

Nicholas Green

 

 

Title:

President & CEO

 

 

 

 

 

By:

 

/s/ Brian Fielding

 

 

Name:

Brian Fielding

 

 

Title:

VP Finance & CFO

 

 

 

 

 

 

 

 

 

INSMED INCORPORATED

 

 

 

By:

 

/s/ Matthew Pauls

 

 

Name:

Matthew Pauls

 

 

Title:

Chief Commercial Officer

 

--------------------------------------------------------------------------------

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS
DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN
ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION.

 

--------------------------------------------------------------------------------

 

APPENDIX I

 

[See attached.]

[***]

 

--------------------------------------------------------------------------------

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS
DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN
ASTERISK [***], HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION.

 

--------------------------------------------------------------------------------